Navigation Links
Verenium Announces Preliminary Financial Results For Fiscal 2012
Date:3/14/2013

results, capital expenditures and cash position, the actual impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position being different from the estimated impact, Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any
'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Markets Inc. (OTCQX: PINK), the financial information and ... quotation and trading system in the U.S. OTC ... (OTCQX: CRMMF, TSX.V: CRM), a Canadian-based medical technology ... highest tier, OTCQX®. (Logo:   http://photos.prnewswire.com/prnh/20090708/NY43125LOGO ...
... DIEGO, Aug. 17 MabVax Therapeutics, Inc., a privately ... of vaccine and antibody based therapies to address the ... it has received a Small Business Innovation Research Grant ... agency,s Streamlined Non-competing Award Procedures (SNAP). Under the SNAP ...
... of only two studies of its kind, a study from ... School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral ... eye disease and preserve vision. The team developed nanoparticles to ... mice temporarily retained more eyesight than controls. The study, published ...
Cached Biology Technology:CRH Medical Corp. Joins OTCQX 2CRH Medical Corp. Joins OTCQX 3MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 2MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 3Breakthrough gene therapy prevents retinal degeneration 2
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be ... Acuity Market Intelligence reports that the long anticipated ... Acuity forecasts that intensifying demand for smart phones, ... will drive a global market of 2.5 billion ... 2020.   According to Maxine ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... A new paper published online in Nature ... type of lung cancer may one day benefit from targeted ... Squamous cell lung cancer kills more people each ... to lung adenocarcinoma in the number of deaths it causes. ...
... extensive forest death triggered by hot and dry climatic ... Forest mortality due to drought and heat stress is ... has focused on isolated incidents of forest mortality, little ... die-offs. A new analysis of the current literature on ...
... applied fertilizer to newly placed sod may result in nutrient ... best time to apply fertilizer and what kind is the ... is a team of scientists from Texas A&M AgriLife Research: ... management; Dr. Ben Wherley, assistant professor of turfgrass science and ...
Cached Biology News:New potential targets discovered for treating squamous cell lung cancers 2New potential targets discovered for treating squamous cell lung cancers 3Forest mortality and climate change: The big picture 2Forest mortality and climate change: The big picture 3Turf study to monitor runoff, establish fertilizer management practices 2
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
... Mass Standards Kit includes reagents that can ... instrument parameters, and calibrate the mass scale ... designed for use with the 4700 Proteomics ... Standards in the kit require minimal preparation ...
...
Biology Products: